KDR and non-small cell lung carcinoma: Interim OS analysis indicated no AEs with ramucirumab plus erlotinib, aligning with current guidelines recommending erlotinib in combination with VEGFR-targeted monoclonal antibodies as first-line therapy for advanced NSCLC.